2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
34
Neoplasms
14
Carcinoma, Non-Small-Cell Lung
10
Colorectal Neoplasms
8
Ovarian Neoplasms
7
Multiple Myeloma
6
Breast Neoplasms
6
Pancreatic Neoplasms
5
Neoplasm Metastasis
4
Hematologic Neoplasms
4
Solid Tumors
3
Neoplasms by Site
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Solid Tumor
2
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Neoplasms by Histologic Type
2
Leukemia, Myelomonocytic, Chronic
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
Carboplatin
12
Paclitaxel
11
Gemcitabine
11
Capecitabine
7
Irinotecan
6
Fluorouracil
5
Cisplatin
5
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Bevacizumab
4
pembrolizumab
3
Filgrastim
3
Etoposide
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
etoposide phosphate
2
atezolizumab
2
Trastuzumab
2
Topotecan
2
Taxes
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Genetic Testing
2
FAPI-46
2
Docetaxel
2
CP protocol
2
Amifostine
2
Albumin-Bound Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
cobimetinib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts